Consistent with the report of Barone et al. [21], we observed that the combination a CXCR4 antagonist with an anti-VEGF antibody was able to reduce tumor growth and increase overall survival in intra-brain U87 xenografts. This evidence concerns the gene VEGFA and neoplasm.